PsychonautWiki Archive

U-47700: Difference between revisions

← Older edit
>LockPicker
Added legal situation in germany
>Tracer
 
(11 intermediate revisions by 10 users not shown)
Line 5: Line 5:
'''U-47700'''<ref>U-47700 at DistilBio | http://www.distilbio.com/show/compound/U-47700</ref> is a synthetic [[psychoactive class::opioid]] substance of the [[chemical class::benzamide]] chemical class that produces [[pain relief|analgesic]], [[muscle relaxation|relaxing]], [[sedation|sedating]] and [[euphoria|euphoric]] effects when [[Routes of administration|administered]].  
'''U-47700'''<ref>U-47700 at DistilBio | http://www.distilbio.com/show/compound/U-47700</ref> is a synthetic [[psychoactive class::opioid]] substance of the [[chemical class::benzamide]] chemical class that produces [[pain relief|analgesic]], [[muscle relaxation|relaxing]], [[sedation|sedating]] and [[euphoria|euphoric]] effects when [[Routes of administration|administered]].  


This compound was initially developed by a team at Upjohn in the 1970s.<ref>Jacob Szmuszkovicz (4 July 1978). "Patent US4098904 - Analgesic n-(2-aminocycloaliphatic)benzamides" | http://www.google.com/patents/US4098904</ref> Upjohn created over a dozen patents on related compounds<ref>Darrell D Mullins (28 June 1966). "Patent US US3258489 - N-(1-aminocyclohexylmethyl)anilines and n-(1-nitrocyclohexylmethyl)an-ilines". | http://www.google.com/patents/US3258489</ref><ref>Norman James Harper, George Bryan Austin Veitch (17 August 1976). "Patent US3975443 - 1-(3,4-dichlorobenzamidomethyl)-cyclohexyldimethylamine". | http://www.google.com/patents/US3975443</ref><ref>http://www.google.com/patents/US3510492</ref><ref>Jacob Szmuszkovicz (5 May 1970). "Patent US3510492 - 2-anilino and 2-anilinomethyl cycloalkylamines". | http://www.google.com/patents/US3510492</ref><ref>Ronald H Rynbrandt, Louis L Skaletzky (7 March 1972). "Patent US3647804 - Cycloalkanecarboxamides". | http://www.google.com/patents/US3510492</ref><ref>W. Roll (23 July 1974). "Patent US3825595 - N-cyclopentyl-n-2-hydroxyalkyl-ring-substituted benzamides". | http://www.google.com/patents/US3825595</ref><ref>Norman James Harper, George Bryan Austin Veitch (20 September 1977). "Patent US4049663 - Ethylene diamine derivatives".</ref><ref>Alan F. Casy, Robert T. Parfitt (1986). Opioid Analgesics, Chemistry and Receptors. Springer US. p. 395. ISBN 978-1-4899-0587-1 | http://www.google.com/patents/US4049663</ref> until they discovered that U-47700 was the most active.<ref>Alan F. Casy, Robert T. Parfitt (1986). Opioid Analgesics, Chemistry and Receptors. Springer US. p. 395. ISBN 978-1-4899-0587-1. | http://link.springer.com/book/10.1007%2F978-1-4899-0585-7</ref> This was done by looking for the key functional groups which gave the greatest activity.<ref>Medicinal agents incorporating the 1,2-diamine functionality. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/2687936</ref>
This compound was initially developed by a team at Upjohn in the 1970s.<ref>{{Citation | vauthors=((Szmuszkovicz, J.)) | title=Analgesic n-(2-aminocycloaliphatic)benzamides | url=https://patents.google.com/patent/US4098904/en}}</ref> Upjohn created over a dozen patents on related compounds<ref>{{Citation | vauthors=((Mullins, D. D.)) | title=N-(1-aminocyclohexylmethyl)anilines and n-(1-nitrocyclohexylmethyl)an-ilines | url=https://patents.google.com/patent/US3258489/en}}</ref><ref>{{Citation | vauthors=((Harper, N. J.)), ((Veitch, G. B. A.)) | title=1-(3,4-dichlorobenzamidomethyl)-cyclohexyldimethylamine | url=https://patents.google.com/patent/US3975443/en}}</ref><ref name="SzmuszkoviczPatent3510492">{{Citation | vauthors=((Szmuszkovicz, J.)) | title=2-anilino and 2-anilinomethyl cycloalkylamines | url=https://patents.google.com/patent/US3510492/en}}</ref><ref>{{Citation | vauthors=((Rynbrandt, R. H.)), ((Skaletzky, L. L.)) | title=Cycloalkanecarboxamides | url=https://patents.google.com/patent/US3647804A/en}}</ref><ref>{{Citation | vauthors=((Roll, W.)) | title=N-cyclopentyl-n-2-hydroxyalkyl-ring-substituted benzamides | url=https://patents.google.com/patent/US3825595/en}}</ref><ref>{{Citation | vauthors=((Roll, W.)) | title=N-cyclopentyl-n-2-hydroxyalkyl-ring-substituted benzamides | url=https://patents.google.com/patent/US3825595/en}}</ref><ref>{{Citation | vauthors=((Harper, N. J.)), ((Veitch, G. B. A.)) | title=Ethylene diamine derivatives | url=https://patents.google.com/patent/US4049663/en}}</ref> until they discovered that U-47700 was the most active.<ref>{{cite book | vauthors=((Casy, A. F.)), ((Parfitt, R. T.)) | date= 1986 | title=Opioid analgesics: chemistry and receptors | publisher=Springer Science+Business Media | url=http://public.ebookcentral.proquest.com/choice/publicfullrecord.aspx?p=3087021 | isbn=9781489905857}}</ref> This was done by looking for the key functional groups which gave the greatest activity.<ref>{{cite journal | vauthors=((Michalson, E. T.)), ((Szmuszkovicz, J.)) | journal=Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques | title=Medicinal agents incorporating the 1,2-diamine functionality | volume=33 | pages=135–149 | date= 1989 | issn=0071-786X | doi=10.1007/978-3-0348-9146-2_6}}</ref>


Very little is known about the toxicity of U-47700 and it has very little history of human usage. It is currently available as a gray-area [[research chemical]] distributed by online vendors. Many reports suggest that it possesses unique physical properties relative to most opioids such as an unusual amount of causticity (ability to destroy living tissue) that may make it significantly more harmful to expose to the body, particularly when it is [[injected]]. It is strongly advised to use [[responsible drug use|harm reduction practices]] if choosing to use this substance.
Very little is known about the toxicity of U-47700 and it has very little history of human usage. It is currently available as a gray-area [[research chemical]] distributed by online vendors. Many reports suggest that it possesses unique physical properties relative to most opioids such as an unusual amount of causticity (ability to destroy living tissue) that may make it significantly more harmful to expose to the body, particularly when it is [[injected]]. It is strongly advised to use [[responsible drug use|harm reduction practices]] if choosing to use this substance.


==Chemistry==
==Chemistry==
U-47700 is an atypical opioid of the benzamide class. It features core phenyl ring with two chlorine atoms at carbons R<sub>3</sub> and R<sub>4</sub>. This ring is connected to an amine group through a carboxyl group (C=O). The terminal nitrogen atom of the amide group is bonded to a methyl carbon and substituted cyclohexane ring. The cyclohexane ring is further substituted at R<sub>2</sub> with a dimethylamino group, thus forming the structure of U-47700.
U-47700 is an atypical opioid of the benzamide class. It features core phenyl ring with two chlorine atoms at carbons R<sub>3</sub> and R<sub>4</sub>. This ring is connected to an amine group through a carbonyl group (C=O). The terminal nitrogen atom of the amide group is bonded to a methyl carbon and substituted cyclohexane ring. The cyclohexane ring is further substituted at R<sub>2</sub> with a dimethylamino group, thus forming the structure of U-47700.


==Pharmacology==
==Pharmacology==
U-47700 is selective for the µ-opioid receptor, with various sources claiming 7.5x the potency of morphine.<ref>B. Vernon Cheney, Jacob Szmuszkovicz, Robert A. Lahti, Dominic A. Zichi (December 1985). "Factors affecting binding of trans-N-[2-(methylamino)cyclohexyl]benzamides at the primary morphine receptor". Journal of Medicinal Chemistry 28 (12): 1853–1864 | http://pubs.acs.org/doi/abs/10.1021/jm00150a017</ref><ref>http://pubs.acs.org/doi/abs/10.1021/jm00257a012</ref>  
U-47700 is selective for the µ-opioid receptor, with various sources claiming 7.5x the potency of morphine.<ref>{{cite journal | vauthors=((Cheney, B. V.)), ((Szmuszkovicz, J.)), ((Lahti, R. A.)), ((Zichi, D. A.)) | journal=Journal of Medicinal Chemistry | title=Factors affecting binding of trans-N-[2-(methylamino)cyclohexyl]benzamides at the primary morphine receptor | volume=28 | issue=12 | pages=1853–1864 | date= December 1985 | url=https://pubs.acs.org/doi/abs/10.1021/jm00150a017 | issn=0022-2623 | doi=10.1021/jm00150a017}}</ref><ref>{{cite journal | vauthors=((Harper, N. J.)), ((Veitch, G. B. A.)), ((Wibberley, D. G.)) | journal=Journal of Medicinal Chemistry | title=1-(3,4-Dichlorobenzamidomethyl)cyclohexyldimethylamine and related compounds as potential analgesics | volume=17 | issue=11 | pages=1188–1193 | date= November 1974 | url=https://pubs.acs.org/doi/abs/10.1021/jm00257a012 | issn=0022-2623 | doi=10.1021/jm00257a012}}</ref>  


Opioids exert their effects by binding to and activating the [[Opioid#Mu_.28.CE.BC.29|μ-opioid]] [[receptor]]. This occurs because opioids structurally mimic endogenous endorphins which are naturally found in the body and also work with the μ-opioid receptor set. The way in which opioids structurally mimic these natural endorphins results in their [[physical euphoria|euphoria]], [[pain relief]] and [[anxiolytic]] effects. This is because endorphins are responsible for reducing pain, causing sleepiness, and feelings of pleasure. They can be released in response to pain, strenuous exercise, orgasm, or general excitement.
Opioids exert their effects by binding to and activating the [[Opioid#Mu_.28.CE.BC.29|μ-opioid]] [[receptor]]. This occurs because opioids structurally mimic endogenous endorphins which are naturally found in the body and also work with the μ-opioid receptor set. The way in which opioids structurally mimic these natural endorphins results in their [[physical euphoria|euphoria]], [[pain relief]] and [[anxiolytic]] effects. This is because endorphins are responsible for reducing pain, causing sleepiness, and feelings of pleasure. They can be released in response to pain, strenuous exercise, orgasm, or general excitement.


U-47700 may also be an agonist for the [[kappa-opioid]] receptor system. As a result of this, it has become the lead compound of selective kappa-opioid receptor ligands such as [[U-50488]] and [[U-69,593]], which share very similar structures.<ref>G. Loew, J. Lawson, L. Toll, G. Frenking, IP. Berzetei-Gurske, W. Polgar (1988). "Structure-activity studies of two classes of beta-amino-amides: the search for kappa-selective opioids." (PDF). NIDA Research Monograph 90: 144–151. | http://archives.drugabuse.gov/pdf/monographs/90.pdf</ref> Its structure led to other chemists experimenting with it to see if rigid analogs would retain activity.<ref>Phenanthridone Analogs of the Opiate Agonist U-47,700 in the trans-1,2-Diaminocyclohexane Benzamide Series | http://www.heterocycles.jp/newlibrary/libraries/abst/07731</ref> Although not used medically, the selective kappa ligands are used in research.<ref>U-50,488 moreover, the к receptor: A personalized account covering the period 1973 to 1990 | http://link.springer.com/chapter/10.1007%2F978-3-0348-8730-4_4</ref>
U-47700 may also be an agonist for the [[kappa-opioid]] receptor system. As a result of this, it has become the lead compound of selective kappa-opioid receptor ligands such as [[U-50488]] and [[U-69,593]], which share very similar structures.<ref>{{cite journal | vauthors=((Loew, G.)), ((Lawson, J.)), ((Toll, L.)), ((Frenking, G.)), ((Berzetei-Gurske, I.)), ((Polgar, W.)) | journal=NIDA research monograph | title=Structure activity studies of two classes of beta-amino-amides: the search for kappa-selective opioids | volume=90 | pages=144–151 | date= 1988 | issn=1046-9516}}</ref> Its structure led to other chemists experimenting with it to see if rigid analogs would retain activity.<ref>{{cite journal | vauthors=((Szmuszkovicz, J.)), ((Zhao, S.)), ((J. Totleben, M.)), ((A. Mizsak, S.)), ((P. Freeman, J.)) | journal=HETEROCYCLES | title=Phenanthridone Analogs of the Opiate Agonist U-47,700 in the trans-1,2-Diaminocyclohexane Benzamide Series | volume=52 | issue=1 | pages=325 | date= 2000 | url=http://www.heterocycles.jp/library/abstract.php?doi=07731 | issn=0385-5414 | doi=10.3987/COM-99-S27}}</ref> Although not used medically, the selective kappa ligands are used in research.<ref>{{cite book | vauthors=((Szmuszkovicz, J.)) | veditors=((Kundu, B.)), ((Khare, S. K.)), ((Ram, V. J.)), ((Goel, A.)), ((Olivier, B.)), ((Soudijn, W.)), ((Wijngaarden, I. van)), ((Szmuszkovicz, J.)), ((Wang, Q. M.)), ((Jucker, E.)) | date= 1999 | chapter=Progress in Drug Research | title=U-50,488 and the к receptor: A personalized account covering the period 1973 to 1990 | publisher=Birkhäuser | series=Progress in Drug Research | pages=167–195 | url=https://doi.org/10.1007/978-3-0348-8730-4_4 | doi=10.1007/978-3-0348-8730-4_4 | isbn=9783034887304}}</ref>


==Subjective effects==
==Subjective effects==
Line 63: Line 63:
{{#ask: [[Category:U-47700]][[Category:Experience]]|format=ul|Columns=1}}
{{#ask: [[Category:U-47700]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:
Additional experience reports can be found here:
* [https://www.erowid.org/experiences/subs/exp_U47700.shtml Erowid Experience Vaults: U-47700]
 
*[https://www.erowid.org/experiences/subs/exp_U47700.shtml Erowid Experience Vaults: U-47700]


==Toxicity and harm potential==
==Toxicity and harm potential==
Line 71: Line 72:
It is worth noting that U-47700 crystals are particularly corrosive and somewhat caustic to mucous membranes. Careless use may deteriorate the chosen [[routes of administration]] so it is important to practice routine maintenance such as soaking the sinus cavity with water prior to and following insufflation. Even if following a regular saline wash of the nasal cavity, multiday use of this substance can create bleeding sores and scabs in the septum and nasal lining. These scabs may persist for days even after all use is ceased. It is unwise to vaporize the substance as it can damage the lungs. Sublingual administration is likely to damage the skin in the mouth.
It is worth noting that U-47700 crystals are particularly corrosive and somewhat caustic to mucous membranes. Careless use may deteriorate the chosen [[routes of administration]] so it is important to practice routine maintenance such as soaking the sinus cavity with water prior to and following insufflation. Even if following a regular saline wash of the nasal cavity, multiday use of this substance can create bleeding sores and scabs in the septum and nasal lining. These scabs may persist for days even after all use is ceased. It is unwise to vaporize the substance as it can damage the lungs. Sublingual administration is likely to damage the skin in the mouth.


Combined consumption of U-47700 and [[fentanyl]] caused one fatality in Belgium.<ref>Twee doden in België door overdosis met fentanylpleisters | http://deredactie.be/cm/vrtnieuws/binnenland/1.2558454</ref> At least 17 opioid overdoses and several deaths in the USA have also been connected with the use of U-47700.<ref>Synthetic opiate makers stay step ahead of US drug laws as overdose cases rise (the Guardian) | http://www.theguardian.com/world/2016/apr/11/synthetic-opiates-drug-laws-w-18-fentanyl</ref>
Combined consumption of U-47700 and [[fentanyl]] caused one fatality in Belgium.<ref>{{Citation | vauthors=((NWS, V.)) | year=2016 | title=Twee doden in België door overdosis met fentanylpleisters | url=https://www.vrt.be/vrtnws/nl/2016/01/29/twee_doden_in_belgiedooroverdosismetfentanylpleisters-1-2558454/}}</ref> At least 17 opioid overdoses and several deaths in the USA have also been connected with the use of U-47700.<ref>{{Citation | vauthors=((Zalkind, S.)) | year=2016 | title=Synthetic opiate makers stay step ahead of US drug laws as overdose cases rise | url=https://www.theguardian.com/world/2016/apr/11/synthetic-opiates-drug-laws-w-18-fentanyl}}</ref>


It is strongly recommended that one use [[responsible drug use|harm reduction practices]], and take extreme caution when using this substance.
It is strongly recommended that one use [[responsible drug use|harm reduction practices]], and take extreme caution when using this substance.
Line 82: Line 83:
[[U-47700]] withdrawal symptoms can be especially painful and emerge after 2-4 hours after the last dose administration. It is highly advisable not to become physically dependent on this substance, as physical dependence can develop in a short period.  
[[U-47700]] withdrawal symptoms can be especially painful and emerge after 2-4 hours after the last dose administration. It is highly advisable not to become physically dependent on this substance, as physical dependence can develop in a short period.  


The risk of fatal opioid overdoses rise sharply after a period of cessation and [[relapse]], largely because of reduced tolerance.<ref>Why Heroin Relapse Often Ends In Death - Lauren F Friedman (Business Insider) | http://www.businessinsider.com.au/philip-seymour-hoffman-overdose-2014-2</ref> To account for this lack of tolerance, it is safer to only dose a fraction of one's usual [[dosage]] if relapsing. It has also been found that the environment one is in can play a role in opioid tolerance. In one scientific study, rats with the same history of heroin administration were significantly more likely to die after receiving their dose in an environment not associated with the drug in contrast to a familiar environment.<ref>Siegel, S., Hinson, R., Krank, M., & McCully, J. (1982). Heroin “overdose” death: contribution of drug-associated environmental cues. Science, 216(4544), 436–437. https://doi.org/10.1126/science.7200260</ref>
The risk of fatal opioid overdoses rise sharply after a period of cessation and [[relapse]], largely because of reduced tolerance.<ref>Why Heroin Relapse Often Ends In Death - Lauren F Friedman (Business Insider) | http://www.businessinsider.com.au/philip-seymour-hoffman-overdose-2014-2</ref> To account for this lack of tolerance, it is safer to only dose a fraction of one's usual [[dosage]] if relapsing. It has also been found that the environment one is in can play a role in opioid tolerance. In one scientific study, rats with the same history of heroin administration were significantly more likely to die after receiving their dose in an environment not associated with the drug in contrast to a familiar environment.<ref>{{cite journal | vauthors=((Siegel, S.)), ((Hinson, R. E.)), ((Krank, M. D.)), ((McCully, J.)) | journal=Science | title=Heroin “Overdose” Death: Contribution of Drug-Associated Environmental Cues | volume=216 | issue=4544 | pages=436–437 | date=23 April 1982 | url=https://www.science.org/doi/10.1126/science.7200260 | issn=0036-8075 | doi=10.1126/science.7200260}}</ref>


===Dangerous interactions===
===Dangerous interactions===
Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
{{DangerousInteractions/Intro}}
*'''[[Depressants]]''' (''[[1,4-Butanediol]], [[2m2b]], [[alcohol]], [[barbiturates]], [[benzodiazepines]], [[GHB]]/[[GBL]], [[methaqualone]]'') - This combination can result in dangerous or even fatal levels of [[respiratory depression]]. These substances potentiate the [[muscle relaxation]], [[sedation]] and [[amnesia]] caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the [https://www.youtube.com/watch?v=uCDa-AhrjHo recovery position] or have a friend move them into it.
{{DangerousInteractions/Opioids}}
*'''[[Dissociatives]]''' - This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the [https://www.youtube.com/watch?v=uCDa-AhrjHo recovery position] or have a friend move them into it.
 
*'''[[Stimulants]]''' -  It is dangerous to combine U-47700, a [[depressant]], with [[stimulant]]s due to the risk of excessive intoxication. Stimulants decrease the [[sedation|sedative]] effect of U-47700, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of U-47700 will be significantly increased, leading to intensified [[disinhibition]] as well as [[U-47700#Subjective effects|other effects]]. If combined, one should strictly limit themselves to only taking a certain amount of U-47700.
==Legal status==


==Legality==
*'''Austria''': U-47700 is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich) as of June 26, 2019.<ref>https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig</ref>
{{legalStub}}
*'''Brazil:''' Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/33868/3233596/55+-+RDC+N%C2%BA+143-2017-DOU.pdf/de80dc69-acb4-48b3-a6ac-1198993b0c1e</ref>
*'''Brazil''' - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/33868/3233596/55+-+RDC+N%C2%BA+143-2017-DOU.pdf/de80dc69-acb4-48b3-a6ac-1198993b0c1e</ref>
*'''Finland:''' U-47700 is an Annex 1 drug in Finland, making its sale, production, and importation illegal.<ref>Lääkeaineluettelo http://www.finlex.fi/fi/laki/kokoelma/2013/sk20130220.pdf</ref>
*'''Sweden''' - Following its sale as a [[designer drug]], U-47700 was made illegal in Sweden on 26 January 2016.<ref>https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/november/31-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara/</ref>
*'''Germany:''' U-47700 is controlled under BtMG Anlage II, making it illegal to manufacture, import, possess, sell, or transfer it without a license.<ref>{{Citation | title=Anlage II BtMG - Einzelnorm | url=http://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html}}</ref>
*'''Finland''' - U-47700 is an Annex 1 drug in Finland, making its sale, production, and importation illegal.<ref>Lääkeaineluettelo http://www.finlex.fi/fi/laki/kokoelma/2013/sk20130220.pdf</ref>
*'''Russia:''' U-47700 is a Schedule I controlled substance.<ref>{{Citation | title=Постановление Правительства РФ от 01.10.2012 N 1002 (ред. от 09.08.2019) “Об утверждении значительного, крупного и особо крупного размеров наркотических средств и психотропных веществ, а также значительного, крупного и особо крупного размеров для растений, содержащих наркотические средства или психотропные вещества, либо их частей, содержащих наркотические средства или психотропные вещества, для целей статей 228, 228.1, 229 и 229.1 Уголовного кодекса Российской Федерации” - КонсультантПлюс | url=https://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=331879&dst=100503&date=03.12.2019}}</ref>
*'''Germany:''' U-47700 is controlled under BtMG Anlage II, making it illegal to manufacture, import, possess, sell, or transfer it without a license.<ref>http://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html</ref>
*'''Sweden:''' Following its sale as a [[designer drug]], U-47700 was made illegal in Sweden on 26 January 2016.<ref>https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/november/31-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara/</ref>
*'''United Kingdom''' - U-47700 is a class A drug in the UK as of 31st May 2017 and is illegal to possess, produce or supply. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2017 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2017/634/made</ref>
*'''Switzerland:''' U-47700 is a controlled substance specifically named under Verzeichnis D.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United States''' - While U-47700 is not scheduled on a federal level, the State of Ohio recently made U-47700 a Schedule I drug. This is not a federal or nationwide action and can only be enforced in the state of Ohio.<ref>Executive Order 2016-01K | http://governor.ohio.gov/Portals/0/pdf/executiveOrders/Executive%20Order%202016-01K.pdf</ref> On September 7th, 2016, the DEA Office of Diversion Control announced that they intend to schedule U-47700 as a Schedule temporarily I drug.<ref>Schedules of Controlled Substances: Temporary Placement of U-47700 Into Schedule I |http://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr0907.htm</ref>
*'''United Kingdom:''' U-47700 is a class A drug in the UK as of 31st May 2017 and is illegal to possess, produce or supply. <ref>{{Citation | title=The Misuse of Drugs Act 1971 (Amendment) Order 2017 | url=https://www.legislation.gov.uk/uksi/2017/634/made}}</ref>
*'''United States:''' While U-47700 is not scheduled on a federal level, the State of Ohio recently made U-47700 a Schedule I drug. This is not a federal or nationwide action and can only be enforced in the state of Ohio.<ref>{{Citation | title=Executive Order 2016-01K | url=https://governor.ohio.gov/Portals/0/pdf/executiveOrders/Executive%20Order%202016-01K.pdf}}</ref> On September 7th, 2016, the DEA Office of Diversion Control announced that they intend to schedule U-47700 as a Schedule temporarily I drug.<ref>Schedules of Controlled Substances: Temporary Placement of U-47700 Into Schedule I |http://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr0907.htm</ref>
*'''Czech Republic''': U-47700 is a Schedule I controlled substance.<ref>{{Citation | vauthors=(([email protected], A. C.-)) | title=463/2013 Sb. Nařízení vlády o seznamech návykových látek | url=https://www.zakonyprolidi.cz/cs/2013-463#f5150333}}</ref>


==See also==
==See also==
*[[Responsible use]]
*[[Responsible use]]
*[[Research chemical]]
*[[Research chemical]]
Line 106: Line 110:


==External links==
==External links==
*[https://en.wikipedia.org/wiki/U-47700 U-47700 (Wikipedia)]
*[https://en.wikipedia.org/wiki/U-47700 U-47700 (Wikipedia)]
*[https://www.erowid.org/chemicals/u-47700/ U-47700 (Erowid Vault)]
*[https://www.erowid.org/chemicals/u-47700/ U-47700 (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=669 U-47700 (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=669 U-47700 (Isomer Design)]
*[https://drugs-forum.com/wiki/U-47700 U-47700 (Drugs-Forum)]
*[http://www.bluelight.org/vb/threads/739960-Novel-opioid-U-47700 U-47700 (Bluelight)]
*[http://www.bluelight.org/vb/threads/739960-Novel-opioid-U-47700 U-47700 (Bluelight)]
*[https://www.reddit.com/r/researchchemicals/comments/35y8b4/been_experimenting_with_u47700_the_last_few_days/ U-47700 (Reddit)]
*[https://www.reddit.com/r/researchchemicals/comments/35y8b4/been_experimenting_with_u47700_the_last_few_days/ U-47700 (Reddit)]
Line 114: Line 120:
=References=
=References=
{{reflist|2}}
{{reflist|2}}
[[Category:Psychoactive substance]]
[[Category:Psychoactive substance]]
[[Category:Cycloalkylamine]]
[[Category:Opioid]]
[[Category:Benzamide]]
[[Category:Research chemical]]
[[Category:Research chemical]]
[[Category:Depressant]]
 
[[Category:Opioid]]
{{#set:Featured=true}}
{{#set:Featured=true}}
Retrieved from "http://psy.st/wiki/U-47700"